Compare GTIM & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | LSTA |
|---|---|---|
| Founded | 1987 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 16.4M |
| IPO Year | 2013 | 2000 |
| Metric | GTIM | LSTA |
|---|---|---|
| Price | $1.21 | $5.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 29.4K | ★ 56.3K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $142,315,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.50 | ★ N/A |
| Revenue Growth | 3.01 | ★ 56.90 |
| 52 Week Low | $1.10 | $1.81 |
| 52 Week High | $2.65 | $5.05 |
| Indicator | GTIM | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 71.30 |
| Support Level | $1.16 | $2.31 |
| Resistance Level | $1.25 | N/A |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.46 | 95.19 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.